Economy · Planned · 2 sources combined
DXVX led by Lim Jong-yoon's side
demands special audit of Hanmi Pharm
D-22 Deadline November 30 · Deadline for DXVX's requested Hanmi Pharmaceuticals audit results submission
In short
DXVX, where Chairman Lim Jong-yoon is the largest shareholder, has demanded a special audit of Hanmi Pharmaceuticals.
The request seeks investigation into the use of corporate credit cards by Chairman Song Young-sook (Lim's mother) and a 70 billion won investment in Aptos.
This is seen as a counter-move that emerged while Hanmi Pharmaceuticals was auditing Beijing Hanmi Pharmaceuticals on Lim's side.
Key facts
| When | On October 23, DXVX sent a shareholder letter to Hanmi Pharmaceuticals' board of directors. |
|---|---|
| Who | DXVX, a listed company where Chairman Lim Jong-yoon of Cory Group is the largest shareholder, made the request. |
| What | Investigation into Chairman Song Young-sook's corporate credit card usage, approximately 70 billion won Aptos investment, and alleged data leak. |
| How | It demands an independent external audit and requests submission of results by November 30. |
What it means for me
Investors holding Hanmi Pharmaceuticals and Hanmi Science shares should monitor stock price movements based on audit results.
